Publisher: American Cancer Society, Wiley

Journal description

The Cancer site is a full-text electronic implementation of Cancer an Interdisciplinary International Journal of the American Cancer Society and its Cancer Cytopathology section. The print and online versions of the journal are published by John Wiley & Sons Inc. The site offers access to current issues since 1997 of Cancer including Cancer Cytopathology in HTML format with embedded links to figures and tables as well as CrossRef links which take users to cited articles that may have been published by a different publisher. There is unrestricted access to tables of contents abstracts and general information about Cancer and the Cancer Cytopathology section as well as to other Wiley journals. The full-text is available to all subscribers following registration . The Cancer Cytopathology section targets these areas: analytic cytopathology fine-needle aspiration gynecologic cytopathology immunocytochemistry molecular diagnostics

Current impact factor: 4.90

Impact Factor Rankings

2015 Impact Factor Available summer 2015
2013 / 2014 Impact Factor 4.901
2012 Impact Factor 5.201
2011 Impact Factor 4.771
2010 Impact Factor 5.131
2009 Impact Factor 5.418
2008 Impact Factor 2.471
2007 Impact Factor 4.632
2006 Impact Factor 4.582
2005 Impact Factor 4.8
2004 Impact Factor 4.434
2003 Impact Factor 4.017
2002 Impact Factor 3.941
2001 Impact Factor 3.909
2000 Impact Factor 3.611
1999 Impact Factor 3.632
1998 Impact Factor 3.66
1997 Impact Factor 3.296

Impact factor over time

Impact factor

Additional details

5-year impact 5.69
Cited half-life 0.00
Immediacy index 1.11
Eigenfactor 0.11
Article influence 2.08
Website Cancer website
Other titles Cancer, Cancer cytopathology
ISSN 0008-543X
OCLC 1553275
Material type Periodical, Internet resource
Document type Journal / Magazine / Newspaper, Internet Resource

Publisher details


  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author cannot archive a post-print version
  • Restrictions
    • 12 months embargo
  • Conditions
    • Some journals have separate policies, please check with each journal directly
    • On author's personal website, institutional repositories, arXiv, AgEcon, PhilPapers, PubMed Central, RePEc or Social Science Research Network
    • Author's pre-print may not be updated with Publisher's Version/PDF
    • Author's pre-print must acknowledge acceptance for publication
    • On a non-profit server
    • Publisher's version/PDF cannot be used
    • Publisher source must be acknowledged with citation
    • Must link to publisher version with set statement (see policy)
    • If OnlineOpen is available, BBSRC, EPSRC, MRC, NERC and STFC authors, may self-archive after 12 months
    • If OnlineOpen is available, AHRC and ESRC authors, may self-archive after 24 months
    • Publisher last contacted on 07/08/2014
    • This policy is an exception to the default policies of 'Wiley'
  • Classification
    ​ yellow

Publications in this journal

  • Cancer 02/2015; 121(3). DOI:10.1002/cncr.29247
  • Cancer 02/2015; 121(3). DOI:10.1002/cncr.29248
  • Cancer 01/2015; 121(2). DOI:10.1002/cncr.29219
  • Cancer 01/2015; 121(2). DOI:10.1002/cncr.29217
  • Cancer 12/2014; 120(23 suppl):3781.
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND There is conflicting evidence regarding the benefit of postmastectomy radiation therapy (PMRT) for pathologic stage T3N0M0 breast cancers. We analyzed data from the Surveillance, Epidemiology, and End Results (SEER) database to investigate the benefit of PMRT in this patient population. METHODS We queried the SEER database for T3N0M0 breast cancer patients diagnosed from 2000 to 2010 who underwent modified radical mastectomy. We excluded males, patients with unknown radiation timing/type, other primary tumors, and survival <6 months. A total of 2525 patients were included in the analysis. We performed univariate and multivariate statistical analysis using chi-square tests, log-rank tests, and Cox proportional hazards regression. The primary endpoints were overall survival (OS) and cancer-specific survival (CSS). RESULTS Of the 2525 patients identified, 1063 received PMRT. The median follow-up was 56 months (range, 6-131 months). On univariate analysis, PMRT improved OS (76.5% vs 61.8%, P<.01) and CSS (85.0% vs 82.4%, P<.01) at 8 years. The use of PMRT remained significant on multivariate analysis: PMRT improved OS (hazard ratio 0.63, P<.001) and CSS (hazard ratio 0.77, P = .045). Low tumor grade (P<.01) and marital status of “married” (P = .01) also was a predictor of improved CSS on multivariate analysis. CONCLUSIONS PMRT was associated with significant improvements in both CSS and OS in patients with T3N0M0 breast cancers treated with modified radical mastectomy from 2000 to 2010. PMRT should be strongly considered in T3N0M0 patients. Postmastectomy radiation therapy is associated with significant improvements in overall and cause-specific survival in patients with T3N0M0 breast cancers treated with modified radical mastectomy from 2000 to 2010 in the SEER database. Postmastectomy radiation therapy should be strongly considered for patients who have T3N0M0 tumors. Cancer 2014. © 2014 American Cancer Society.
    Cancer 11/2014; 120(22):n/a-n/a. DOI:10.1002/cncr.28865
  • [Show abstract] [Hide abstract]
    ABSTRACT: Validated measures of empowerment for cancer patients will be very useful for program interventions. In this editorial, the author reviews the 2 articles in this issue that used the Health Education Information Questionnaire and suggests other important populations to study.
    Cancer 10/2014; 120(20). DOI:10.1002/cncr.28852
  • [Show abstract] [Hide abstract]
    ABSTRACT: Adolescents and young adults with cancer have inferior survival outcomes compared with younger pediatric patients and older adult patients. Lack of insurance may partly explain this disparity. The objective of this study was to identify associations between insurance status and both advanced-stage cancer and cancer-specific mortality. Using the Surveillance, Epidemiology, and End Results (SEER) 18 registries, 57,981 patients ages 15 to 39 years were identified who were diagnosed between 2007 and 2010 and had complete insurance and staging information. Multinomial logistic regression models were used to identify associations between insurance type and disease stage, with the models adjusted for sex, age, and race. Cox proportional hazards models were used to estimate cancer-specific mortality. Overall, 84% of patients were aged ≥25 years, 64% were women, and 79% were privately insured. Compared with patients who had private insurance, those who had nonprivate insurance tended to present with more advanced-stage disease and to die more quickly and more commonly from their cancer. Patients ages 25 to 39 years who had Medicaid coverage or no insurance had 3.2 times and 2.4 times higher odds of having stage IV disease, respectively, than privately insured patients (95% confidence interval [CI], 3.0-3.5 times higher odds and 2.1-2.6 times higher odds, respectively). Among those with stage I/II and III/IV cancers, the risk of death was 2.9 times greater (95% CI, 2.2-3.9 times greater) and 1.7 times greater (95% CI, 1.5-1.9 times greater), respectively, than the risk for privately insured patients. Patients who died from stage III/IV cancers survived at least 2 months longer if they had private insurance. Among young adults, insurance status is independently associated with advanced-stage cancer and the risk of death from cancer, even for patients who have low-stage disease. Broader insurance coverage and access to health care may improve some of the disparate outcomes of adolescents and young adults with cancer. Cancer 2015. © 2014 American Cancer Society. © 2014 American Cancer Society.
    Cancer 12/2014; In press. DOI:10.1002/cncr.29187
  • Source
    Cancer 07/2014; 120(14):2069-71. DOI:10.1002/cncr.28872
  • Source
    Cancer 07/2014; 120(14):2071. DOI:10.1002/cncr.28873
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND The neutrophil-to-lymphocyte ratio (NLR), a marker of inflammation, has been reported to be a poor prognostic indicator in prostate cancer. Here we explore the use of the NLR to establish a simple prognostic score for men with metastatic castration-resistant prostate cancer (mCRPC) treated with docetaxel. METHODS: In the training cohort, the NLR and other known prognostic variables were evaluated among a cohort of chemotherapy-naive patients treated with thrice-weekly docetaxel at the Princess Margaret Cancer Centre. Significant prognostic variables identified by univariable Cox regression were evaluated by the area under the receiver operating characteristic curves. Multivariable Cox regression was then used to derive a prognostic score where 1 risk point was assigned for each significant variable. The model was externally validated in a cohort of patients treated at the Royal Marsden. RESULTS: Three hudred fifty-seven patients were analyzed in the training cohort. Median age was 71 years, 12% had liver metastasis, and median overall survival (OS) was 14.7 months. Liver metastases, hemoglobin <12 g/dL, alkaline phosphatase >2.0x upper limit of normal (ULN), lactate dehydrogenase >1.2x ULN, and NLR >3 were associated with significantly worse OS in multivariable analysis. Four risk categories were subsequently established with 0, 1, 2, and 3-5 points. Two-year OS rates for these categories were 43%, 37%, 12%, and 3%, respectively. Area under the curve for the training cohort was 0.78 (95% CI, 0.72-0.84) compared with 0.66 (95% CI, 0.58-0.74) for the 215 patients in the validation cohort. CONCLUSIONS: This simple risk score provides good prognostic and discriminatory accuracy for men with mCRPC. Cancer 2014;120:3346-3352. (c) 2014 American Cancer Society.
    Cancer 11/2014; 120(21). DOI:10.1002/cncr.28890
  • [Show abstract] [Hide abstract]
    ABSTRACT: Medical and surgical oncologists involved in the management of patients with sarcoma know well that the management of those with recurrent chondrosarcoma is quite challenging. In light of the currently available data, anthracycline‐based chemotherapy and radiotherapy represent reasonable options for chondrosarcoma patients not eligible to a clinical trial with good performance status and who have unresectable metastatic or locally advanced disease, respectively.
    Cancer 10/2014; 120(20). DOI:10.1002/cncr.28842
  • [Show abstract] [Hide abstract]
    ABSTRACT: Community-based cancer organizations provide services to support patients. An anticipated benefit of these services is patient empowerment. However, this outcome has not been evaluated because of the lack of validated health-related empowerment questionnaires in the cancer context. In this validation study, the authors assessed the extent to which 16 indicators used by the Canadian Cancer Society (CCS) and the Cancer Council Victoria, Australia (CCV) to evaluate their services were associated with health-related empowerment.
    Cancer 07/2014; 120(20). DOI:10.1002/cncr.28846
  • [Show abstract] [Hide abstract]
    ABSTRACT: Recent data indicate that chemotherapy treats cancer, at least in part, by facilitating an immune response to the tumor. The study results outlined in this issue highlight the potential benefits in devising an optimal strategy for integrating new immune-based therapies into the standard of care for various cancers.
    Cancer 11/2014; 120(21). DOI:10.1002/cncr.28883
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND The primary objective of this study was to determine the safety and maximum tolerated dose (MTD) of the antimesothelin immunotoxin SS1(dsFv)PE38 (SS1P) (a recombinant antimesothelin immunotoxin consisting of a murine antimesothelin variable antibody fragment [Fv] linked to PE38, a truncated portion of Pseudomonas exotoxin A) in combination with pemetrexed and cisplatin in chemotherapy-naive patients with advanced malignant pleural mesothelioma (MPM). Secondary objectives included tumor response, SS1P pharmacokinetics, and serum biomarkers of response. METHODS Chemotherapy-naive patients with stage III or IV, unresectable, epithelial or biphasic MPM and normal organ functions were eligible. Pemetrexed (500 mg/m(2) on day 1) and cisplatin (75 mg/m(2) on day 1) were administered every 3 weeks for up to 6 cycles with escalating doses of SS1P administered intravenously on days 1, 3, and 5 during cycles 1 and 2. Tumor response was evaluated every 6 weeks. RESULTSTwenty-four patients received SS1P at 4 dose levels from 25 to 55 mcg/kg. Grade 3 fatigue was dose-limiting in 1 patient at 55 mcg/kg. The MTD of SS1P was established as 45 mcg/kg. Other grade 3 toxicities associated with SS1P included hypoalbuminemia (21%), back pain (13%), and hypotension (8%). Of 20 evaluable patients, 12 (60%) had a partial response, 3 had stable disease, and 5 had progressive disease. Of 13 patients who received the MTD, 10 (77%) had a partial response, 1 had stable disease, and 2 had progressive disease. Objective radiologic responses were associated with significant decreases in serum mesothelin (P=.0030), megakaryocyte potentiating factor (P=.0005), and cancer antigen 125 (P<.0001). CONCLUSIONSSS1P given with pemetrexed and cisplatin is safe and well tolerated and exhibits significant antitumor activity in patients with unresectable, advanced pleural mesothelioma. Serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125 levels correlated with objective tumor responses. Cancer 2014;120:3311-3319. Published 2014. This article is a U.S. Government work and is in the public domain in the USA. In this first clinical evaluation of the combination of an immunotoxin with chemotherapy, SS1P, an antimesothelin immunotoxin, was combined with pemetrexed and cisplatin in chemotherapy-naive patients who had advanced malignant pleural mesothelioma. The results from this phase 1 trial demonstrate that SS1P and chemotherapy can be safely combined with no overlapping toxicity. In addition, the objective tumor response rate for the combination is higher than expected with chemotherapy alone and provides a strong rationale for a randomized trial to confirm this finding.
    Cancer 11/2014; 120(21). DOI:10.1002/cncr.28875
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: T-cell lymphomas (TCLs) are uncommon in the United States. The accurate diagnosis of TCL is challenging and requires morphologic interpretation, immunophenotyping, and molecular techniques. The authors compared pathologic diagnoses at referring centers with diagnoses from expert hematopathology review to determine concordance rates and to characterize the usefulness of second-opinion pathology review for TCL. METHODS: Patients in the National Comprehensive Cancer Network non-Hodgkin lymphoma database with peripheral TCL, not otherwise specified (PTCL-NOS), angioimmunoblastic TCL (AITL), and anaplastic lymphoma kinase (ALK)-positive and ALK-negative anaplastic large cell lymphoma (ALCL) were eligible if they had prior tissue specimens examined at a referring institution. Pathologic concordance was evaluated using available pathology and diagnostic testing reports and provider progress notes. The etiology of discordance and the potential impact on treatment were examined. RESULTS: Among 131 eligible patients, 57 (44%) had concordant results, totaling 64% of the 89 patients who were referred with a final diagnosis. Thirty-two patients (24%) had discordant results, representing 36% of those who were referred with a final diagnosis. The rates of discordance among patients with of PTCL-NOS, AITL, ALK-negative ALCL, and ALK-positive ALCL were 19%, 33%, 34%, and 6%, respectively. In 14 patients (44% of discordant results), pathologic reclassification could have resulted in a different therapeutic strategy. Forty-two patients (32%) were referred for classification with a provisional diagnosis. CONCLUSIONS: In a large cohort of patients with TCL who were referred to National Comprehensive Cancer Network centers, the likelihood of a concordant final diagnosis at a referring institution was low. As current and future therapies target TCL subsets, these data suggest that patients with suspected TCLs would benefit from evaluation by an expert hematopathologist. (C) 2014 American Cancer Society.
    Cancer 07/2014; 120(13):1993-9. DOI:10.1002/cncr.28676
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: The authors investigated the prevalence, determinants of, and disparities in any perceived unmet need for 8 supportive services (home nurse, support group, psychological services, social worker, physical/occupational rehabilitation, pain management, spiritual counseling, and smoking cessation) by race/ethnicity and nativity and how it is associated with perceived quality of care among US patients with lung cancer. METHODS: Data from a multiregional, multihealth system representative cohort of 4334 newly diagnosed patients were analyzed. Binomial logistic regression models adjusted for patient clustering. RESULTS: Patients with any perceived unmet need (9% overall) included 7% of white-US-born (USB), 9% of white-foreign-born (FB), 13% of black-USB, 8% of Latino-USB, 24% of Latino-FB, 4% of Asian/Pacific Islander (API)-USB, 14% of API-FB, and 11% of "other" patients (P<.001). Even after controlling for demographic and socioeconomic factors, health system and health care access, and need, black-USB, Latino-FB, and Asian-FB patients were more likely to perceive an unmet need than white-USB patients by 5.1, 10.9, and 5.6 percentage points, respectively (all P<.05). Being younger, female, never married, uninsured, a current smoker, or under surrogate care or having comorbidity, anxiety/depression, or a cost/insurance barrier to getting tests/treatments were associated with any unmet need. Patients with any unmet need were more likely to rate care as less-than-"excellent" by 13 percentage points than patients with no unmet need (P<.001). CONCLUSIONS: Significant disparities in unmet supportive service need by race/ethnicity and nativity highlight immigrants with lung cancer as being particularly underserved. Eliminating disparities in access to needed supportive services is essential for delivering patient-centered, equitable cancer care. (C) 2014 American Cancer Society.
    Cancer 07/2014; 120(20). DOI:10.1002/cncr.28801